Skip to main content
Premium Trial:

Request an Annual Quote

Norrie Russell Joins Invitrogen as VP, Peter Wagner Takes Helm at Zyomyx, Tim Germann Becomes VP of Sales and Marketing at US Genomics, Steve Fodor to Receive 2005 ABRF Award, and Others

Norrie Russell has joined Invitrogen as vice president and general manager of its functional genomics strategic business unit, the company said last week. Most recently, he was president and CEO of Aviva Biosciences. Prior to that, he was president and CEO of Lynx Therapeutics. Russell holds a PhD in physiology from GlasgowUniversity in Scotland.


Peter Wagner has been promoted to CEO of Zyomyx, the company said yesterday, replacing Robert Monaghan. Wagner, a company co-founder, has been Zyomyx's chief technology officer since 1998.


Tim Germann has assumed the newly created position of vice president of sales and marketing for US Genomics, the company said yesterday. Prior to his new post, he was the northeast sales manager for Affymetrix. Before that, he held sales or management positions at Stratagene, Genometrix, Incyte Genomics, and Molecular Devices. Germann holds a BS degree in business management from Brigham Young University.


Paul James has resigned as senior vice president of commercial operations of Biacore International, the company said yesterday. His resignation was unexpected and "due to personal family reasons," the company said in a statement. Biacore his currently searching for a successor and plans to fill James' post by early 2005. In the meantime, company CEO Erik Wallden will be responsible for all of Biacore's commercial operations.


Anthony Altig has become CFO and senior vice president of finance of Diversa, the company said yesterday. He joins Diversa from Maxim Pharmaceuticals, where he was CFO. Altig holds a degree from the Universityof Hawaii.


David Bellitt has become president of the new Atlanta-based Celliance division of Serologicals, the company said on Monday. He joined Serologicals in 2002 as vice president for global commercial operations and will remain corporate vice president.


Jeff Schneiderhas become chief informatics officer of PsychoGenics, the company said on Monday. He has been a research scientist at Carnegie Mellon's Robotics Institute since 1998, and he is a co-founder of Schenley Park Research, an artificial intelligence company. At PsychoGenics, he will lead a bioinformatics team.


Göran Ando has been appointed to the board of directors of Enzon Pharmaceuticals, the company said on Monday. Prior to becoming CEO of Celltech in 2003, he held a number of senior R&D posts at Pharmacia. Ando holds an MD from LinkopingUniversity in Sweden.


Gary Costleyhas been elected to the board of directors of NanoBio, the Ann Arbor, Mich.-based company said yesterday. Costley also serves on the board of directors of Accelrys, among other companies.


Werner Dubitzky has joined the scientific advisory board of GenoMed, the St. Louis-based company said yesterday. He is a professor and chair of bioinformatics at the Schoolof Biomedical Sciencesof the University of Ulster at Coleraine. Dubitzky holds a PhD in artificial intelligence and machine learning from the Universityof Ulster in Northern Irelandand a BSc in electrical and communication engineering from the University of Applied Science in Augsburg, Germany.


Gordon Wasserman has filled a newly created slot on the board of directors of Orchid BioSciences, the company said today. He is the CEO of his own consulting firm that specializes in the management of police agencies, particularly scientific and technological support services. Wasserman served as assistant under secretary of state for police science and technology in the UKgovernment for more than 10 years. He has also been an adviser to the police commissioners of New York Cityand Philadelphia, the chiefs of police of Miami, Hartfordand other UScities, the US Department of Justice, and several other national governments. Wasserman holds BA and MA degrees from OxfordUniversity and a BA from McGillUniversity.


Alan Hollingsworthhas joined the scientific advisory board of Power3 Medical Products, the proteomics company said today. He is the medical director at Mercy Women's Center in Oklahoma City.


Non-profit group Creative Commons has tapped John Wilbanks to serve as executive director of Science Commons, a newly formed branch of the organization that will address copyright issues related to scientific data. Wilbanks is currently a W3C fellow at the Worldwide Web Consortium focusing on the semantic web for life sciences.


IO Informaticshas appointed Blaine Bowman and Richard Freyberg to its board of directors. Bowman is chairman of the board of directors of Dionex. Freyberg was previously CIO of Schwab Capital Markets.


Pratik Shah joined Thomas, McNerney & Partners of San Franciscoas a new venture partner, the firm said last week. Pratik was most recently the chief business officer and co-founder of Kalypsys, a San Diegobiotech company. Previously, Pratik was at McKinsey & Co. where he focused on biotechnology and venture capital projects. Thomas, McNerney & Partners is a private equity firm that invests in life science and medical technology companies.


John Bergeron will receive the McLaughlin Medal from the Royal Society of Canada, the CanadianAcademyof the Sciences and Humanities, at the society's awards banquet on Nov. 20. He is a professor and chair of anatomy and cell biology at McGillUniversityand director of the Montreal Proteomics Network. He is also the current president of HUPO. Bergeron holds a doctorate from OxfordUniversity and an undergraduate degree in biochemistry from McGillUniversity.


Steve Fodor, chairman and CEO of Affymetrix, will receive the 2005 ABRF Award from the Association of Biomolecular Resource Facilities at the organization's annual meeting in Savannah, Ga., in February 2005.


Al Kolb is currently serving as the 2004-2005 president elect for the Society for Biomolecular Screening, the organization announced last week. He will assume the presidency at the society's 11th Annual Conference and Exhibition, to be held Sept. 11-15 in Geneva. Kolb is a consultant for KeyTechnology Consulting in Madison, Conn.He holds a PhD in molecular biology from the Universityof California, Irvine, and completed a postdoctoral fellowship at the Roche Institute for Molecular Biology.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.